Merit Medical to Begin Sales of Wrapsody, Pulls Government Payment Application

Dow Jones11-14

By Terell Wright

Merit Medical Systems will immediately begin selling its Wrapsody medical device and withdraw its application for government transitional pass-through incremental funding

The decision comes after the Centers for Medicare & Medicaid Services deferred the application for Wrapsody--a cell-impermeable endoprosthesis used in outpatient settings--making Jan. 1, 2027, the earliest approval date.

The disposable medical device manufacturer's Chief Executive Martha Aronson said Thursday recent clinical data supports the effectiveness of the device in treating hemodialysis patients.

The company maintained that U.S. revenue from Wrapsody will be between $2 million and $4 million for the full year.

Shares declined 8.5% to $80 in post market trading. Through the market's close the stock is down 9.6% this year.

Write to Terell Wright at terell.wright@wsj.com

(END) Dow Jones Newswires

November 13, 2025 17:04 ET (22:04 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2583510575?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-14 06:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2583510575","market":"nz","top_or_hot":-1,"title":"Merit Medical to Begin Sales of Wrapsody, Pulls Government Payment Application","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Terell Wright \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/MMSI\">Merit Medical Systems</a> will immediately begin selling its Wrapsody medical device and withdraw its application for government transitional pass-through incremental funding \n</p>\n<p>\n  The decision comes after the Centers for Medicare &amp; Medicaid Services deferred the application for Wrapsody--a cell-impermeable endoprosthesis used in outpatient settings--making Jan. 1, 2027, the earliest approval date. \n</p>\n<p>\n  The disposable medical device manufacturer's Chief Executive Martha Aronson said Thursday recent clinical data supports the effectiveness of the device in treating hemodialysis patients. \n</p>\n<p>\n  The company maintained that U.S. revenue from Wrapsody will be between $2 million and $4 million for the full year. \n</p>\n<p>\n  Shares declined 8.5% to $80 in post market trading. Through the market's close the stock is down 9.6% this year. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Terell Wright at terell.wright@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 13, 2025 17:04 ET (22:04 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Merit Medical to Begin Sales of Wrapsody, Pulls Government Payment Application</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMerit Medical to Begin Sales of Wrapsody, Pulls Government Payment Application\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-11-14 06:04</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Terell Wright \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/MMSI\">Merit Medical Systems</a> will immediately begin selling its Wrapsody medical device and withdraw its application for government transitional pass-through incremental funding \n</p>\n<p>\n  The decision comes after the Centers for Medicare &amp; Medicaid Services deferred the application for Wrapsody--a cell-impermeable endoprosthesis used in outpatient settings--making Jan. 1, 2027, the earliest approval date. \n</p>\n<p>\n  The disposable medical device manufacturer's Chief Executive Martha Aronson said Thursday recent clinical data supports the effectiveness of the device in treating hemodialysis patients. \n</p>\n<p>\n  The company maintained that U.S. revenue from Wrapsody will be between $2 million and $4 million for the full year. \n</p>\n<p>\n  Shares declined 8.5% to $80 in post market trading. Through the market's close the stock is down 9.6% this year. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Terell Wright at terell.wright@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 13, 2025 17:04 ET (22:04 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MMSI","symbol_name":"Merit Medical Systems","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2583510575","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2583510575","pubTimestamp":1763071440,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Merit Medical Systems will immediately begin selling its Wrapsody medical device and withdraw its application for government transitional pass-through incremental funding. The decision comes after the Centers for Medicare & Medicaid Services deferred the application for Wrapsody--a cell-impermeable endoprosthesis used in outpatient settings--making Jan. 1, 2027, the earliest approval date.The disposable medical device manufacturer's Chief Executive Martha Aronson said Thursday recent clinical data supports the effectiveness of the device in treating hemodialysis patients.The company maintained that U.S. revenue from Wrapsody will be between $2 million and $4 million for the full year.Shares declined 8.5% to $80 in post market trading. Through the market's close the stock is down 9.6% this year.","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"MMSI":"Merit Medical Systems"},"translate_title":"Merit Medical开始销售Wrapsody，撤回政府付款申请","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MMSI":1.5},"content_text":"By Terell Wright \n\n\n \n\n\nMerit Medical Systems will immediately begin selling its Wrapsody medical device and withdraw its application for government transitional pass-through incremental funding \n\n\n  The decision comes after the Centers for Medicare & Medicaid Services deferred the application for Wrapsody--a cell-impermeable endoprosthesis used in outpatient settings--making Jan. 1, 2027, the earliest approval date. \n\n\n  The disposable medical device manufacturer's Chief Executive Martha Aronson said Thursday recent clinical data supports the effectiveness of the device in treating hemodialysis patients. \n\n\n  The company maintained that U.S. revenue from Wrapsody will be between $2 million and $4 million for the full year. \n\n\n  Shares declined 8.5% to $80 in post market trading. Through the market's close the stock is down 9.6% this year. \n\n\n \n\n\n  Write to Terell Wright at terell.wright@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 13, 2025 17:04 ET (22:04 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2583510575","isCrawlerRequest":true}